Quantcast

Latest exemestane Stories

2014-09-27 08:21:23

- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER, N.J., Sept. 27, 2014 /PRNewswire/ -- Novartis today presented final results on overall survival (OS) from a Phase III trial of Afinitor(®) (everolimus) tablets plus best supportive care (BSC) compared to placebo plus BSC in patients with well-differentiated advanced and progressive pancreatic...

2014-07-30 08:33:06

Studies Support Ongoing Clinical Strategy of Using Syndax's Entinostat as Epigenetic Priming to Immune Therapy WALTHAM, Mass., July 30, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced that newly published results demonstrate that in preclinical studies entinostat significantly improved treatment outcomes in mouse tumor models when combined with anti-PD1 and anti-CTLA4 targeted antibodies. The paper from Kim, et al. at The Sidney Kimmel Comprehensive Cancer Center,...

2014-06-30 23:10:00

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in trial E2112. PHILADELPHIA, Pa. and WALTHAM, Mass. (PRWEB) June 30, 2014 The ECOG-ACRIN Cancer Research Group and Syndax Pharmaceuticals Inc. announced today enrollment of the first patient in E2112, a randomized phase III clinical trial of Syndax’s histone deacetylase (HDAC) inhibitor, entinostat, for the treatment of patients with advanced breast...

2014-05-27 08:28:53

WALTHAM, Mass., May 27, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced that clinical trial data on entinostat will be presented in two posters during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30 - June 3, 2014, in Chicago. The first poster, titled "Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer," is being...

2014-04-01 23:26:52

Italian researchers say a drug used to treat breast cancer appears to shrink mesothelioma tumors, too. Raleigh, NC (PRWEB) April 01, 2014 The breast cancer drug Aromasin may offer a new way to treat malignant pleural mesothelioma, according to research conducted at Italy. Click here to read details of the new study, available now on the Surviving Mesothelioma website. Cancer researchers with Regina Elena National Cancer Institute in Rome have concluded that the drug Aromasin...

2014-03-27 20:21:46

WALTHAM, Mass., March 27, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Syndax. The number of shares to be offered and the price range for the offering have not yet been determined. Deutsche Bank...

2014-03-20 23:22:02

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112. Philadelphia, PA, and Waltham, MA (PRWEB) March 20, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Syndax Pharmaceuticals, Inc., announced today that patient recruitment has begun for E2112, a randomized phase III clinical trial of Syndax’s entinostat in treatment of patients with advanced breast cancer. The...

2014-02-13 08:30:49

WALTHAM, Mass., Feb. 13, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has reached a special protocol assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the planned pivotal Phase 3 trial of entinostat in patients with advanced breast cancer. The Phase 3 trial, expected to begin in the first half of this year, is intended to evaluate...

2014-02-03 08:27:30

WALTHAM, Mass., Feb. 3, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W. Sledge, Jr., M.D., to its board of directors as an independent director. Dr. Sledge is currently professor and chief of medical oncology at Stanford University Medical Center. He specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced...

2014-01-23 08:30:59

WALTHAM, Mass., Jan. 23, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. today announced the appointment of Richard P. Shea to its board of directors as an independent director and chairman of the audit committee. Mr. Shea is an experienced biotechnology executive with wide ranging experience in finance and operations as well as managing venture financings, initial public offerings, secondary offerings and mergers and acquisitions. Mr. Shea is currently senior vice president and...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related